Jama Author Interviews: Covering Research In Medicine, Science, & Clinical Practice. For Physicians, Researchers, & Clinician

Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF), but it is not consistently improved by any of the current guideline-directed medical therapies. JAMA Deputy Editor Gregory Curfman, MD, discusses whether omecamtiv mecarbil can improve peak exercise capacity in patients with HFrEF with Gregory D. Lewis, MD, from Massachusetts General Hospital, and Mark H. Drazner, MD, MSc, from University of Texas Southwestern Medical Center. Related Content: Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial Omecamtiv Mecarbil as a Therapy for Heart Failure With Low Ejection Fraction